12 October 2023
12 October 2023
The Phase III trial of ALK’s allergy immunotherapy tablet met its primary endpoint for the treatment of tree-pollen-induced allergic rhinoconjunctivitis.
Approved in 2022, Rinvoq demonstrated sustained treatment effect and safety profile at week 140 in atopic dermatitis patients.
Patients treated with Opzelura in the extended Phase III True-V trial showed symptom improvement after previously showing no response to treatment.
The study demonstrated continued the efficacy, safety and the absence of rebound upon washout of the drug.
The study achieved both primary and key secondary endpoints with high statistical significance.
A trial into a vaccine to combat cat allergies has been greenlit by the UK's Medicines and Healthcare Products Regulatory Agency.
Bexmarilimab boasts a 50% remission rate for patients with AML and MDS who have proved resistant to other last-resort therapies.
Six-month randomized controlled trial in the US evaluates the efficacy of MODIA in conjunction with sublingual buprenorphine naloxone for the treatment of opioid abuse.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
